Study of T-DXd Monotherapy in Patients with HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma who have Received 2 or More Prior Regimens

Trial Identifier: D9676C00002
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo Co., Ltd.
NCTID:: NCT04989816
Start Date: August 2021
Primary Completion Date: February 2024
Study Completion Date: February 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100191
CN Beijing, CN, 100142
CN Changsha, CN, 410008
CN Chengdu, CN, 610042
CN Fuzhou, CN, 350014
CN guangzhou, CN, 510062
CN Hangzhou, CN, 310003
CN Hangzhou, CN, 310020
CN Hangzhou, CN, 310009
CN Hefei, CN, 230022
CN Hefei, CN, 230031
CN Hefei, CN, 230001
CN Jinan, CN, 250001
CN Lanzhou, CN, 730030
CN Nan Chong, CN, 637000
CN nanchang, CN, 330029
CN Nanjing, CN, 210009
CN Shanghai, CN, 200032
CN shenyang, CN, 110001
CN Suzhou, CN, 215006
CN Wuhan, CN, 430030
CN Wuhan, CN, 430000
CN Xiamen, CN, 361003
CN Yinchuan, CN, 750004
CN Zhengzhou, CN, 450008
CN Zhengzhou City, CN, 450000